Tumour necrosis factor alpha (TNFa) is increased in peak VO 2 (r=0.54), and soluble TNF receptors 1 (r=−0.56) and 2 (r=−0.52, all p<0.002). patients with cardiac cachexia, a condition associated with reduced peripheral blood flow both at TNFa, soluble TNF receptors 1 and 2 and aldosterone correlated with peak blood flow independrest and after interventions causing vasodilation. By contrast, in patients with chronic heart failure ently of age, ejection fraction, peak VO 2 and functional NYHA class. TNFa was the only para-(CHF), higher TNF levels are associated with a greater capacity for vasodilation in the arm. To meter that showed strong correlations for peak blood flow in all clinically relevant subgroups clarify the relationship between peripheral blood flow and TNF in CHF, we studied the relation (severe vs. mild, ischaemic vs. dilated, cachectic vs. non-cachectic patients). This study shows a close between TNFa and blood flow in the leg (plethysmography, post maximal exercise and 5 min ischand inverse relationship between peak leg blood flow and the plasma concentration of TNFa, sugaemia) in 34 patients (age 63±2 years, ejection fraction 29±3%, peak VO 2 16.6±1.1 ml/kg/min, gesting a pathophysiological role for TNFa in reducing peak peripheral blood flow in CHF. mean±SEM). Peak leg blood flow correlated significantly with total TNFa (r=−0.68, p<0.0001),
Introduction
Reduced peripheral blood flow in patients with patients with severe CHF, especially in cachectic patients. This was confirmed by other groups.7,8 chronic heart failure (CHF) is attributed to a reduced cardiac output, and to excessive vasoconstrictor tone.
TNFa is a key cytokine for the initiation of catabolism.9 It was recently reported10 that patients with The reduced peripheral blood flow is linked to the symptoms and clinical features of patients with heart CHF and high TNFa levels had higher post-ischaemic forearm blood flows and higher blood flow responses failure.1 Significant correlations between peak limb blood flow and exercise capacity (maximal oxygen to administration of acetylcholine and nitroglycerin; these observations were attributed to increased consumption (peak VO 2 ) , have been demonstrated in these patients,1,2 but not consistently.3, 4 We have activation of inducible NO synthase. 10 The findings
have not yet been confirmed in other clinical studies, shown previously that peak leg blood flow predicted peak VO 2 only in CHF patients with cachexia.5 but there is in vitro evidence for the suggested mechanism of increased NO production (reviewed In 1990, Levine et al.6 demonstrated elevated plasma levels of tumour necrosis factor (TNFa) in in reference 11). This is surprising, as healthy subjects have low TNFa levels but high peak blood flows, using the Quantikine high sensitivity (0.5 pg/ml) kit from R&D Systems to validate our results. This test whereas patients with severe CHF have elevated TNFa levels but reduced peripheral blood flow. The kit measures intact TNF trimers, and is also not influenced by soluble TNF receptors. The cytokines objective of the present study was, therefore, to clarify the relation between peak blood flow and as well as hGH, IGF-I, insulin and aldosterone, were measured in duplicate. Unless otherwise stated, data cytokines in patients with CHF, taking into account disease severity and factors that are known to influin this paper refer to total TNF levels measured with the Medgenix kit. All other parameters were analysed ence peripheral vasodilation. The studies on blood flow were made in the leg rather than the arm.
by the routine analysis of our hospital.
Functional tests

Methods
Maximal oxygen consumption (peak VO 2
Patients
in ml/kg/min) was measured by treadmill exercise testing.3 Ultrafast computerized tomography Thirty-four men (age 62.6±2.0 years, range 34-83 (Imatron) was used to determine the muscle crossyears, mean±SEM) with stable heart failure of at sectional area of the right thigh transaxially at midleast 6 months duration were investigated (left ventrifemur level.3 Leg blood flow in the right leg was cular ejection fraction by nuclear scan: 29±3%). determined using venous occlusion plethysmography All studies were performed within a maximum of 2 (EC4, Hokanson) after at least 10 min rest, and peak days, arranged so that the blood samples were always flow after exercise and an additional 5 min taken in the fasting state between 9 and 10 am. Two ischaemia.4 patients were in functional New York Heart Association (NYHA) class I, 13 in class II, 15 in
Statistical analysis
class III, and 4 in class IV. Sixteen patients had signs of clinical cachexia, whereas 18 patients were nonResults are presented as means±SEM. We used cachectic. Patients with clinical cachexia were simple linear regression to analyse the predictors of defined as those with a documented weight loss of peak leg blood flow (StatView 4.5, Abacus Concepts). Á7.5% of previous normal weight (range 8-30%)
As 30 clinical and biochemical/haematological paraover a period of Á6 months.12 The patients were meters were analysed, a probability value of on stable medication for at least 4 weeks prior to p<0.00167 was considered statistically significant the study. The patients were being treated with (Bonferroni correction). Subgroup analyses were subdiuretics (n=31), ACE inhibitors (26), aspirin (12), sequently only performed for those factors that fulwarfarin (11), digitalis (10), oral nitrates (9) , and filled these criteria and correlated independently of calcium antagonists (2) in varying combinations. No age. Multivariate analysis and stepwise regressions patients had signs of renal failure, acute infection, were also performed and here p<0.05 was considperipheral or pulmonary oedema, hepatomegaly or ered statistically significant. ascites. All patients gave written informed consent. The protocol was approved by the Ethics Committee of the Royal Brompton Hospital, London.
Results
Blood samples Physiological tests
Standard venous blood samples were obtained after The CHF patients had a mean peak VO 2 of overnight fasting and 20 min supine rest. After centri-16.6±1.1 ml/kg/min. The cross-sectional area of the fugation, aliquots were stored at −70°C until anaright thigh muscles amounted to 103.3±4.0 cm2. lysis. Human growth hormone (hGH), insulin-like
The right leg blood flow at rest was 2.9± growth factor-1 (IGF-I), and aldosterone were meas-0.2 ml/100ml/min (range 1.05-5.76 ml/100ml/min), ured using radio-immunoassays.13 TNFa was measincreasing to a peak of 24.1±1.3 ml/100 ml/min ured using an immunoassay with a lower limit of (range 7.89-37.50 ml/100ml/min). The results of the detectability of 3.0 pg/ml (Medgenix). The latter is blood tests are presented in Table 1 . an ELISA test using three antibodies directed against distinct epitopes of TNFa that is not influenced by Peak leg blood flow correlation soluble TNF receptors.14 Additionally, we investigated the levels of soluble There was a significant univariate correlation between peak leg blood flow and peak VO 2 (r= TNF receptor-1 (sTNFR1), sTNFR2, interleukin-1b (IL-1b) and IL-6 by ELISA.15 In a subset of 26 patients, 0.54, p=0.001). Due to the chosen significance level, age (r=0.47, p=0.005), BMI (r=0.37, we were able to perform an additional TNFa assay * Three patients had levels below 0.02 ng/ml (limit of detectability). ** Four patients had levels below 3.00 pg/ml (limit of detectability). *** Seven patients had levels below 0.01 pg/ml (limit of detectability). (For these parameters a value at the limit of detectability was recorded for statistical analyses.)
p<0.05), total area of the thigh muscles (r=0.41, p<0.01) and right thigh cross-sectional area (r= 0.36, p<0.05) did not correlate significantly with peak leg blood flow. Three cytokines correlated significantly and inversely with peak leg blood flow: TNFa (r=−0.68, p<0.0001, Figure 1 ), sTNFR1 (r=−0.56, p=0.0005), and sTNFR2 (r=−0.52, p=0.0016). There were trends for a correlation between peak blood flow and hGH (r=−0.48, p= 0.004) and aldosterone (r=−0.41, p<0.05), but no significant correlations with left ventricular ejection fraction (r=0.08), NYHA class (r=−0.19), or any of the other measured biochemical or haematological factors. On multivariate analysis, TNFa ( p<0.0001), sTNFR1, aldosterone (both p=0.006), sTNFR2 ( p= 0.02), hGH, and peak VO 2 (in ml/kg/min, both p= 0.04) correlated with peak leg blood flow independently of age. The following factors also correlated independently of ejection fraction, NYHA class and peak VO 2 : TNFa ( p=0.001), sTNFR1 ( p=0.006), aldosterone ( p=0.02) and sTNFR2 ( p=0.03). In multivariate analysis with only the latter four factors, r2=0.463, p<0.0001, F-value 27.56). After adjusting for TNFa, only hGH (F-value 6.98) and the inducible form of NO synthase might potentially only be seen at these higher concentrations. Katz age (F-value 4.46) were significantly related to peak et al. measured peak blood flows in the forearm blood flow. The best two-step model was: TNFa and after 5 min ischaemia, whereas we investigated peak hGH together vs. peak leg blood flow: r=−0.75, leg blood flows in response to exercise plus an r2=0.561, p<0.0001. The principal results were additional 5 min ischaemia. confirmed using a second test kit for the assessment TNFa may amplify agonist-induced NO expresof TNFa (R&D systems, data not shown). To analyse sion. But TNFa may also blunt blood flow responses whether the observed correlations were related to a to exercising muscle. The latter effects could be of specific group of heart failure patients, the study greater importance in cardiac cachexia, when TNFa population was subgrouped by NYHA class, the is chronically elevated6 and peak leg blood flow presence of cachexia, and the disease aetiology.
becomes the best predictor of exercise capacity.5 Only total TNFa (r=−0.50 to −0.74) was a strong Multiple factors increase or decrease the effects of predictor of peak leg blood flow in all analysed TNFa, and its actions vary between tissues. For subgroups (data not shown).
instance, when TNFa levels are elevated in plasma, it may contribute to skeletal muscle cachexia,
Correlates of TNFa
whereas local TNFa production in the brain causes anorexia.9 In endothelial cells, TNFa can cause Simple regression analysis showed significant inverse rearrangement of the cytoskeleton, increased percorrelations between TNFa and peak leg blood flow meability to albumin and water, enhanced expression (Figure 1 ), leg muscle size (r=−0.55, p=0.0007) of activation antigens, induction of surface procoaguas well as peak VO 2 (r=−0.54, p=0.0009), and a lant activity and IL-1 release.16 All of these actions positive relation to sTNFR1 and sTNFR2 (both r= could impair endothelial function. 0.67, p<0.0001).
At the molecular level, TNFa increases the expression of inducible NO synthase in vascular endothelial cells,17 but also reduces constitutive NO synthase Discussion mRNA in these cells.18 TNFa reduces the half-life of NO, and increases superoxide anion release of The principal finding of this study is that TNFa is endothelial cells,19 the latter being potentially damsignificantly and inversely related to peak leg blood aging to the endothelium. Additionally, TNFa may flow in patients with CHF. This relation is seen in affect other cell systems that are important for patients with CHF independently of clinical disease vasodilation, such as the calcium transport severity, age, disease aetiology and the presence of system.20,21 These conflicting actions, and the fact cachexia.
that tolerance to TNFa action can result from proOur findings differ from the results of Katz and longed exposure,22 may also explain the differing colleagues10 who demonstrated that CHF patients results between our study and that of Katz et al.10 with higher TNFa levels showed higher post-
The reasons for these differences are not known. ischaemic blood flows and better blood flow responses to acetylcholine. Those authors10 found Limitations no significant correlation between peak or resting blood flows and TNFa levels in the 10 heart failure The total amount of TNFa measured in plasma patients with detectable amounts of TNF. There are consists of the total amount of free TNFa molecules important differences between their study and ours. and the amount of TNFa bound to soluble receptors Katz et al.10 had no patients with ischaemic heart (TNF-R1 and TNF-R2). Both types of TNFa receptor disease (here 19/34), none in functional NYHA class can affect TNFa bioactivity.23 Both test kits used IV (here 4/34), and none had sodium levels measure TNFa, whether receptor-bound or free. We <136 mmol/l (here 9/34). Our heart failure patients did not directly measure the bioactivity of TNF in were slightly older (63±11 vs. 58±11, mean±SD) the blood samples of these CHF patients. This study and we included cardiac cachectic patients (not does, however, show a close relationship between specified by Katz et al.10) . Differences between the peak leg blood flow and the plasma concentration arm and leg circulations in CHF potentially exist, of TNFa. This may indicate a significant pathophysiand they may partly explain the findings. Another ological role for TNFa in CHF, i.e. that raised TNFa potentially important area of difference is the use of contributes to impaired peripheral vasodilation. different ELISA test kits with different sensitivities (20 pg/ml vs. 3 pg/ml). The TNFa concentrations reported by Katz et al.10 were higher than in our
